Clinical trials
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,720 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07783100RecruitingPhase 2
Combination treatment for relapsed or refractory acute myeloid leukemia
This study tests a combination of three drugs (venetoclax, chidamide, and chiglitazar) for people with acute myeloid leukemia (AML) that has not responded to standard treatment or has returned. The goal is to see if this combination can help control the leukemia and is safe.
Xiamen, FujianAges 18 years+ - NCT07767630RecruitingEarly Phase 1
Targeted radiation therapy for relapsed neuroblastoma
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
Chengdu, SichuanAges 1–100 - NCT07774520RecruitingPhase 2
Lower dose of lazertinib plus magnesium to prevent nerve damage in advanced lung cancer
This trial tests a lower starting dose of the targeted therapy drug lazertinib combined with magnesium supplements to prevent a common side effect (peripheral neuropathy) in people with advanced lung cancer caused by certain EGFR mutations. The goal is to see if this approach keeps the drug effective while reducing nerve damage symptoms like numbness or tingling.
Seoul, Gang-nam GuAges 19 years+ - NCT06567197Recruiting
MS treatment with stem cell transplant in the Netherlands
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
AmsterdamAges 18–65 - NCT05830123RecruitingPhase 2
Test drug HS-20093 for osteosarcoma after earlier treatment
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
BeijingAges 18 years+ - NCT07742215RecruitingPhase 3
Combination treatment for relapsed or refractory multiple myeloma
This trial tests a new drug (BCD-248) combined with daratumumab for people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to see if this combination can help control the cancer better.
HomyelAges 18 years+ - NCT07725380RecruitingPhase 1/Phase 2
Two drugs for relapsed sarcoma or osteosarcoma
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Tampa, FloridaAges 12–40 - NCT07715630RecruitingPhase 1
PICX CAR-T therapy for relapsed or hard-to-treat multiple myeloma
This trial tests a new treatment called PICX CAR-T, a type of immune cell therapy, for multiple myeloma that has come back or not responded well to at least two prior treatments. It aims to see if this therapy can help control the disease.
Kunming, YunnanAges 18 years+ - NCT05299424RecruitingPhase 1/Phase 2
CM336 for multiple myeloma after prior treatments
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07710534RecruitingPhase 2
A study of decitabine-cedazuridine and venetoclax for blood cancers
This trial tests a combination of two drugs (decitabine-cedazuridine and venetoclax) that are given in a low-dose, frequent schedule (metronomic) for people with certain blood cancers that have come back or not responded to treatment. The goal is to see if this combo can help control the disease.
Richmond, VirginiaAges 18 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT04587856Recruiting
Study why blood cancer returns after donor stem cell transplant
This study looks at why a bone marrow disorder (MDS) can come back after a donor stem cell transplant. It may help researchers understand relapse, which could improve future care for people getting transplants.
BariAges 18 years+ - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT07674498Recruiting
Immune health in older adults with advanced myeloma
This trial studies the immune system of adults 65 and older with multiple myeloma that has come back or not responded to treatment. It looks at how their immune fitness may affect their ability to receive newer therapies like CAR-T cells or bispecific antibodies.
Anderlecht, Brussels CapitalAges 65 years+ - NCT06644118RecruitingPhase 1
Study of OL-101 for people with relapsed or refractory multiple myeloma
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75 - NCT07629596RecruitingEarly Phase 1
mRNA CAR-T therapy for severe lupus or autoimmune anemia
This early-stage trial tests a new mRNA-based therapy called Arnovie101 that trains your immune cells to fight lupus (SLE) or autoimmune hemolytic anemia (AIHA) that haven't improved with standard treatments. The therapy may help reduce disease activity and symptoms.
Beijing, Beijing MunicipalityAges 18–60 - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Los Angeles, CaliforniaAges 1 month–17 years - NCT07637578RecruitingPhase 2
Elranatamab infusions for relapsed or refractory myeloma
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Denver, ColoradoAges 18 years+ - NCT07623616RecruitingPhase 2
Ziftomenib for relapsed AML with NPM1 mutation
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
ChibaAges 18 years+ - NCT07620041RecruitingPhase 1
Testing QLC5508, a new cancer drug, in advanced solid tumors
This early-stage trial tests QLC5508, an experimental cancer medication, in patients with advanced solid tumors that haven't responded to standard treatments. The study focuses on safety, how the drug moves through your body, and potential interactions with other medications.
Changchun, JilinAges 18 years+ - NCT07604064RecruitingPhase 2
IDH1 Inhibitor Treatment for Relapsed or Refractory Blood Cancer
This trial tests a drug called olutasidenib in Japanese patients with acute myeloid leukemia (a serious blood cancer) that has come back or stopped responding to previous treatment. The drug targets a specific genetic change (IDH1 mutation) that some leukemia cells have, and may help patients whose cancer is difficult to treat.
Tokyo and Other Japanese CitiesAges 18 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 1,720 recruiting relapsed or refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.